Cargando…
Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness
The role of negative checkpoint regulators (NCRs) in human health and disease cannot be overstated. V-domain Ig-containing Suppressor of T-cell Activation (VISTA) is an Ig superfamily protein predominantly expressed within the hematopoietic compartment and has been studied for its role in the negati...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877598/ https://www.ncbi.nlm.nih.gov/pubmed/31803182 http://dx.doi.org/10.3389/fimmu.2019.02641 |
_version_ | 1783473366005448704 |
---|---|
author | Broughton, Thomas W. K. ElTanbouly, Mohamed A. Schaafsma, Evelien Deng, Jie Sarde, Aurélien Croteau, Walburga Li, Jiannan Nowak, Elizabeth C. Mabaera, Rodwell Smits, Nicole C. Kuta, Anna Noelle, Randolph J. Lines, J. Louise |
author_facet | Broughton, Thomas W. K. ElTanbouly, Mohamed A. Schaafsma, Evelien Deng, Jie Sarde, Aurélien Croteau, Walburga Li, Jiannan Nowak, Elizabeth C. Mabaera, Rodwell Smits, Nicole C. Kuta, Anna Noelle, Randolph J. Lines, J. Louise |
author_sort | Broughton, Thomas W. K. |
collection | PubMed |
description | The role of negative checkpoint regulators (NCRs) in human health and disease cannot be overstated. V-domain Ig-containing Suppressor of T-cell Activation (VISTA) is an Ig superfamily protein predominantly expressed within the hematopoietic compartment and has been studied for its role in the negative regulation of T cell responses. The findings presented in this study show that, unlike all other NCRs, VISTA deficiency dramatically impacts on macrophage cytokine and chemokine production, as well as the chemotactic response of VISTA-deficient macrophages. A select group of inflammatory chemokines, including CCL2, CCL3, CCL4, and CCL5, was strikingly elevated in culture supernatants from VISTA KO macrophages. VISTA deficiency also altered chemokine receptor recycling and profoundly disrupted myeloid chemotaxis. The impact of VISTA deficiency on chemotaxis in vivo was apparent with the reduced ability of both KO macrophages and MDSCs to migrate to the tumor microenvironment. This is the first demonstration of an NCR impacting on myeloid mediator production and chemotaxis, and will guide the use of anti-VISTA therapeutics to manipulate the chemotaxis of inflammatory macrophages or immunosuppressive MDSCs in inflammatory diseases and cancer. |
format | Online Article Text |
id | pubmed-6877598 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68775982019-12-04 Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness Broughton, Thomas W. K. ElTanbouly, Mohamed A. Schaafsma, Evelien Deng, Jie Sarde, Aurélien Croteau, Walburga Li, Jiannan Nowak, Elizabeth C. Mabaera, Rodwell Smits, Nicole C. Kuta, Anna Noelle, Randolph J. Lines, J. Louise Front Immunol Immunology The role of negative checkpoint regulators (NCRs) in human health and disease cannot be overstated. V-domain Ig-containing Suppressor of T-cell Activation (VISTA) is an Ig superfamily protein predominantly expressed within the hematopoietic compartment and has been studied for its role in the negative regulation of T cell responses. The findings presented in this study show that, unlike all other NCRs, VISTA deficiency dramatically impacts on macrophage cytokine and chemokine production, as well as the chemotactic response of VISTA-deficient macrophages. A select group of inflammatory chemokines, including CCL2, CCL3, CCL4, and CCL5, was strikingly elevated in culture supernatants from VISTA KO macrophages. VISTA deficiency also altered chemokine receptor recycling and profoundly disrupted myeloid chemotaxis. The impact of VISTA deficiency on chemotaxis in vivo was apparent with the reduced ability of both KO macrophages and MDSCs to migrate to the tumor microenvironment. This is the first demonstration of an NCR impacting on myeloid mediator production and chemotaxis, and will guide the use of anti-VISTA therapeutics to manipulate the chemotaxis of inflammatory macrophages or immunosuppressive MDSCs in inflammatory diseases and cancer. Frontiers Media S.A. 2019-11-19 /pmc/articles/PMC6877598/ /pubmed/31803182 http://dx.doi.org/10.3389/fimmu.2019.02641 Text en Copyright © 2019 Broughton, ElTanbouly, Schaafsma, Deng, Sarde, Croteau, Li, Nowak, Mabaera, Smits, Kuta, Noelle and Lines. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Broughton, Thomas W. K. ElTanbouly, Mohamed A. Schaafsma, Evelien Deng, Jie Sarde, Aurélien Croteau, Walburga Li, Jiannan Nowak, Elizabeth C. Mabaera, Rodwell Smits, Nicole C. Kuta, Anna Noelle, Randolph J. Lines, J. Louise Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title | Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title_full | Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title_fullStr | Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title_full_unstemmed | Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title_short | Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness |
title_sort | defining the signature of vista on myeloid cell chemokine responsiveness |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6877598/ https://www.ncbi.nlm.nih.gov/pubmed/31803182 http://dx.doi.org/10.3389/fimmu.2019.02641 |
work_keys_str_mv | AT broughtonthomaswk definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT eltanboulymohameda definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT schaafsmaevelien definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT dengjie definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT sardeaurelien definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT croteauwalburga definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT lijiannan definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT nowakelizabethc definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT mabaerarodwell definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT smitsnicolec definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT kutaanna definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT noellerandolphj definingthesignatureofvistaonmyeloidcellchemokineresponsiveness AT linesjlouise definingthesignatureofvistaonmyeloidcellchemokineresponsiveness |